<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00575185</url>
  </required_header>
  <id_info>
    <org_study_id>0709M16341</org_study_id>
    <nct_id>NCT00575185</nct_id>
  </id_info>
  <brief_title>Activity of Valomaciclovir in Infectious Mononucleosis Due to Primary Epstein-Barr Virus Infection</brief_title>
  <acronym>Mono6</acronym>
  <official_title>Randomized, Placebo-Controlled, Double-Blind Study to Assess Clinical and Antiviral Activity of Valomaciclovir (EPB 348) in Infectious Mononucleosis Due to Primary Epstein-Barr Virus Infection (Mono 6)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Epiphany Biosciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a randomized, placebo-controlled, double-blind single-center proof of concept
      study to evaluate the anti-EBV activity of 4 grams of valomaciclovir (2 grams BID) for 21
      days in subjects with infectious mononucleosis documented to be caused by primary EBV
      infection. Otherwise healthy subjects (≥15 years old) referred to us with a clinical
      diagnosis of primary infectious mononucleosis will be screened and those with
      laboratory-confirmed primary EBV infection will be enrolled.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be seen 2 times a week for 3 weeks and then weekly for 3 weeks. Clinical
      findings, clinical lab tests, EBV viral loads, and EBV antibody titers will be obtained at
      each clinic visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Improvement in Clinical Symptoms and Reductions in Viral Burden From Baseline</measure>
    <time_frame>21 days</time_frame>
    <description>All subjects had confirmed cases of EB and will be assessed for Improvement of clinical symptoms (ie: tiredness, nausea etc)and reduction in viral burden from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Adverse Events During the Study Safety and Tolerability</measure>
    <time_frame>15 days</time_frame>
    <description>Assessing adverse events in participants to see if this drug causes more or less side effects</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Infectious Mononucleosis</condition>
  <arm_group>
    <arm_group_label>Valomaciclovir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Valomaciclovir 2 grams orally twice daily for 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo 2 tablets twice daily for 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valomaciclovir</intervention_name>
    <description>4 grams orally of valomaciclovir (2 grams BID) for 21 days.</description>
    <arm_group_label>Valomaciclovir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo tablets orally twice daily for 21 days.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 15 years or older

          -  Within 14 days of initial symptoms of present illness diagnosed by a health care
             provider as infectious mononucleosis and confirmed to be due to primary EBV by
             antibody profile. The criteria for antibody confirmation of primary EBV at the
             screening visit are: 1)Positive for anti-EBV VCA IgM antibody and negative for
             anti-EBV EBNA1 IgG antibody; 2)EBV antibody testing will be done in the Clinical
             Virology Research Laboratory using commercial ELISA kits (Diamedix Corporation, Miami,
             FL).

          -  Willingness to sign the Informed Consent Form (ICF)

          -  Willingness to contribute samples of blood and oral washings at regular intervals

          -  Males and females must use effective contraception during treatment and for at least
             90 days following treatment

          -  Negative pregnancy test result at the Screening Visit for females of childbearing
             potential (including females who have had a bilateral tubal ligation). Female patients
             of childbearing potential must be willing to use an approved method of double-barrier
             contraception (hormonal plus barrier or barrier plus barrier, eg, diaphragm plus
             condom) from the time of first dose administration until 90 days after completion of
             dosing and male patients with female partners of childbearing potential must be
             willing to use a condom. Patients who are sterile or infertile (defined as those who
             are postmenopausal or have undergone a complete hysterectomy) are eligible.

          -  Estimated creatinine clearance (Cockcroft and Gault method) ≥ 60 ml/min

          -  Absolute neutrophil count ≥ 1000 cells/microliter

          -  Platelets ≥ 100,000/microliter

          -  Hemoglobin ≥ 9.5 g/dL

        Exclusion Criteria:

          -  Previous history of infectious mononucleosis-like illness

          -  Immunosuppressed due to medical disease and/or immunosuppressive or immunomodulating
             medications (e.g., corticosteroids prior to enrollment, cytotoxic drugs, interferons)

          -  Another intercurrent viral infection (including HIV), based on history or referring
             physician medical evaluation

          -  More than 7 days elapsed since onset of illness (including screening time)

          -  The following concomitant medications are prohibited: probenecid, trimethoprim,
             myelosuppressive therapies, and medications known to be nephrotoxic

          -  Breast feeding during the study

          -  Corticosteroids are not permitted. If they are prescribed by the subject's primary
             physician for treatment of this acute disease after the subject has enrolled, the
             subject will be replaced.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henry H Balfour, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Laboratory Medicine &amp; Pathology, and Pediatrics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Balfour HH Jr, Holman CJ, Hokanson KM, Lelonek MM, Giesbrecht JE, White DR, Schmeling DO, Webb CH, Cavert W, Wang DH, Brundage RC. A prospective clinical study of Epstein-Barr virus and host interactions during acute infectious mononucleosis. J Infect Dis. 2005 Nov 1;192(9):1505-12. Epub 2005 Sep 26.</citation>
    <PMID>16206064</PMID>
  </reference>
  <reference>
    <citation>Balfour HH Jr, Hokanson KM, Schacherer RM, Fietzer CM, Schmeling DO, Holman CJ, Vezina HE, Brundage RC. A virologic pilot study of valacyclovir in infectious mononucleosis. J Clin Virol. 2007 May;39(1):16-21. Epub 2007 Mar 21.</citation>
    <PMID>17369082</PMID>
  </reference>
  <reference>
    <citation>Rea TD, Russo JE, Katon W, Ashley RL, Buchwald DS. Prospective study of the natural history of infectious mononucleosis caused by Epstein-Barr virus. J Am Board Fam Pract. 2001 Jul-Aug;14(4):234-42.</citation>
    <PMID>11458965</PMID>
  </reference>
  <reference>
    <citation>Cameron B, Galbraith S, Zhang Y, Davenport T, Vollmer-Conna U, Wakefield D, Hickie I, Dunsmuir W, Whistler T, Vernon S, Reeves WC, Lloyd AR; Dubbo Infection Outcomes Study. Gene expression correlates of postinfective fatigue syndrome after infectious mononucleosis. J Infect Dis. 2007 Jul 1;196(1):56-66. Epub 2007 May 24.</citation>
    <PMID>17538884</PMID>
  </reference>
  <reference>
    <citation>Torre D, Tambini R. Acyclovir for treatment of infectious mononucleosis: a meta-analysis. Scand J Infect Dis. 1999;31(6):543-7.</citation>
    <PMID>10680982</PMID>
  </reference>
  <reference>
    <citation>Silins SL, Sherritt MA, Silleri JM, Cross SM, Elliott SL, Bharadwaj M, Le TT, Morrison LE, Khanna R, Moss DJ, Suhrbier A, Misko IS. Asymptomatic primary Epstein-Barr virus infection occurs in the absence of blood T-cell repertoire perturbations despite high levels of systemic viral load. Blood. 2001 Dec 15;98(13):3739-44.</citation>
    <PMID>11739180</PMID>
  </reference>
  <reference>
    <citation>Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol. 2007;25:587-617. Review.</citation>
    <PMID>17378764</PMID>
  </reference>
  <reference>
    <citation>Hislop AD, Kuo M, Drake-Lee AB, Akbar AN, Bergler W, Hammerschmitt N, Khan N, Palendira U, Leese AM, Timms JM, Bell AI, Buckley CD, Rickinson AB. Tonsillar homing of Epstein-Barr virus-specific CD8+ T cells and the virus-host balance. J Clin Invest. 2005 Sep;115(9):2546-55. Epub 2005 Aug 18.</citation>
    <PMID>16110323</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2007</study_first_submitted>
  <study_first_submitted_qc>December 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2007</study_first_posted>
  <results_first_submitted>December 3, 2014</results_first_submitted>
  <results_first_submitted_qc>March 13, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 17, 2015</results_first_posted>
  <last_update_submitted>February 16, 2017</last_update_submitted>
  <last_update_submitted_qc>February 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mono</keyword>
  <keyword>Mononucleosis</keyword>
  <keyword>Epstein-Barr virus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
    <mesh_term>Epstein-Barr Virus Infections</mesh_term>
    <mesh_term>Infectious Mononucleosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>University of Minnesota students that contracted Mono and wsere seen at the student health center</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Valomaciclovir</title>
          <description>Valomaciclovir 2 grams orally twice daily for 21 days
Valomaciclovir : 4 grams orally of valomaciclovir (2 grams BID) for 21 days.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>placebo 2 tablets twice daily for 21 days
placebo : Placebo tablets orally twice daily for 21 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>College students infected with mono</population>
      <group_list>
        <group group_id="B1">
          <title>Valomaciclovir</title>
          <description>Valomaciclovir 2 grams orally twice daily for 21 days
Valomaciclovir : 4 grams orally of valomaciclovir (2 grams BID) for 21 days.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo 2 tablets twice daily for 21 days
placebo : Placebo tablets orally twice daily for 21 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>particpants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Improvement in Clinical Symptoms and Reductions in Viral Burden From Baseline</title>
        <description>All subjects had confirmed cases of EB and will be assessed for Improvement of clinical symptoms (ie: tiredness, nausea etc)and reduction in viral burden from baseline</description>
        <time_frame>21 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Valomaciclovir</title>
            <description>Valomaciclovir 2 grams orally twice daily for 21 days
Valomaciclovir : 4 grams orally of valomaciclovir (2 grams BID) for 21 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo 2 tablets twice daily for 21 days
placebo : Placebo tablets orally twice daily for 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Improvement in Clinical Symptoms and Reductions in Viral Burden From Baseline</title>
          <description>All subjects had confirmed cases of EB and will be assessed for Improvement of clinical symptoms (ie: tiredness, nausea etc)and reduction in viral burden from baseline</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Adverse Events During the Study Safety and Tolerability</title>
        <description>Assessing adverse events in participants to see if this drug causes more or less side effects</description>
        <time_frame>15 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Valomaciclovir</title>
            <description>Valomaciclovir 2 grams orally twice daily for 21 days
Valomaciclovir: 4 grams orally of valomaciclovir (2 grams BID) for 21 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo 2 tablets twice daily for 21 days
placebo: Placebo tablets orally twice daily for 21 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Adverse Events During the Study Safety and Tolerability</title>
          <description>Assessing adverse events in participants to see if this drug causes more or less side effects</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Valomaciclovir</title>
          <description>Valomaciclovir 2 grams orally twice daily for 21 days
Valomaciclovir : 4 grams orally of valomaciclovir (2 grams BID) for 21 days.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo 2 tablets twice daily for 21 days
placebo : Placebo tablets orally twice daily for 21 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hank Balfour MD</name_or_title>
      <organization>University of Minnesota</organization>
      <phone>(612) 626-5670</phone>
      <email>balfo001@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

